QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
Log in
NASDAQ:CATB

Catabasis Pharmaceuticals Stock Forecast, Price & News

$1.50
+0.04 (+2.74 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.45
Now: $1.50
$1.58
50-Day Range
$1.32
MA: $3.37
$6.63
52-Week Range
$1.25
Now: $1.50
$8.59
Volume1.34 million shs
Average Volume498,403 shs
Market Capitalization$30.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
Read More
Catabasis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971
Employees27

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$2.46 per share

Profitability

Net Income$-26,290,000.00

Miscellaneous

Market Cap$30.13 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$1.50
+0.04 (+2.74 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

How has Catabasis Pharmaceuticals' stock been impacted by COVID-19?

Catabasis Pharmaceuticals' stock was trading at $4.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CATB stock has decreased by 66.2% and is now trading at $1.50.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Catabasis Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Catabasis Pharmaceuticals
.

What stocks does MarketBeat like better than Catabasis Pharmaceuticals?

Wall Street analysts have given Catabasis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catabasis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Catabasis Pharmaceuticals
.

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) posted its quarterly earnings results on Tuesday, November, 17th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.05.
View Catabasis Pharmaceuticals' earnings history
.

When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work?

Shares of Catabasis Pharmaceuticals reverse split on Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CATB?

3 analysts have issued 1-year price targets for Catabasis Pharmaceuticals' shares. Their forecasts range from $15.00 to $60.00. On average, they anticipate Catabasis Pharmaceuticals' share price to reach $33.00 in the next year. This suggests a possible upside of 2,100.0% from the stock's current price.
View analysts' price targets for Catabasis Pharmaceuticals
.

Are investors shorting Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals saw a decrease in short interest in the month of October. As of October 30th, there was short interest totaling 644,100 shares, a decrease of 18.1% from the October 15th total of 786,800 shares. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is presently 0.6 days.
View Catabasis Pharmaceuticals' Short Interest
.

Who are some of Catabasis Pharmaceuticals' key competitors?

What other stocks do shareholders of Catabasis Pharmaceuticals own?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the following people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 52, Pay $734.54k)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 59, Pay $512.64k)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 63, Pay $594.41k)
  • Mr. Noah Clauser CPA, Chief Financial Officer (Age 47)
  • Mr. Benjamin S. Harshbarger J.D., Sr. VP & Gen. Counsel (Age 51)
  • Mr. Joseph Johnston, Sr. VP of Regulatory Affairs
  • Mr. Andrew A. Komjathy, Chief Commercial Officer (Age 57)
  • Ms. Andrea L. Matthews, VP of Corp. Affairs

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (1.27%), Wells Fargo & Company MN (0.68%), WINTON GROUP Ltd (0.23%), Schonfeld Strategic Advisors LLC (0.07%), Schonfeld Strategic Advisors LLC (0.07%) and JPMorgan Chase & Co. (0.07%).
View institutional ownership trends for Catabasis Pharmaceuticals
.

Which major investors are selling Catabasis Pharmaceuticals stock?

CATB stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd.
View insider buying and selling activity for Catabasis Pharmaceuticals
.

Which major investors are buying Catabasis Pharmaceuticals stock?

CATB stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, State Street Corp, Schonfeld Strategic Advisors LLC, Schonfeld Strategic Advisors LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Catabasis Pharmaceuticals
.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $1.50.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $30.13 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-26,290,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. Catabasis Pharmaceuticals employs 27 workers across the globe.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is www.catabasis.com.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is 100 High StreetFloor 28, Boston MA, 02110. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.